Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 9Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 24Carcinoma, Intraductal, Noninfiltrating 6Breast Carcinoma In Situ 3Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Pinealoma 1Pancreatic Neoplasms 1Pancreatic Cyst 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms by Site 1Neoplasm Metastasis 1Medulloblastoma 1Infertility 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HR Positive HER2 Negative Advanced Breast Cancer 1Glioblastoma 1ERα+ Breast Cancer 1ER+ Breast Cancer 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

ribociclib 2exemestane 2abemaciclib 2Tamoxifen 2Letrozole 2Anastrozole 2palbociclib 1elacestrant 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Standard of Care 1Practice Guidelines as Topic 1Methods 1Leuprolide 1Interviews as Topic 1Goserelin 1Genetic Counseling 1Educational Status 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms, Male × Tamoxifen × Clear all
NCT06492616 2026-05-27

ELEGANT

Stemline Therapeutics, Inc.

Phase 3 Recruiting
4,220 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT05501704 2026-04-30

ETHAN - ET for Male BC

Dana-Farber Cancer Institute

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡